169 related articles for article (PubMed ID: 15602589)
1. Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy.
Scherr M; Battmer K; Schultheis B; Ganser A; Eder M
Gene Ther; 2005 Jan; 12(1):12-21. PubMed ID: 15602589
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
Sengupta A; Banerjee D; Chandra S; Banerjee S
J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
[TBL] [Abstract][Full Text] [Related]
3. Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells.
Arthanari Y; Pluen A; Rajendran R; Aojula H; Demonacos C
J Control Release; 2010 Aug; 145(3):272-80. PubMed ID: 20403398
[TBL] [Abstract][Full Text] [Related]
4. Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference.
Bártová E; Harnicarová A; Pacherník J; Kozubek S
Leuk Res; 2005 Aug; 29(8):901-13. PubMed ID: 15978941
[TBL] [Abstract][Full Text] [Related]
5. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
[TBL] [Abstract][Full Text] [Related]
6. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
[TBL] [Abstract][Full Text] [Related]
7. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi).
Wilda M; Fuchs U; Wössmann W; Borkhardt A
Oncogene; 2002 Aug; 21(37):5716-24. PubMed ID: 12173041
[TBL] [Abstract][Full Text] [Related]
8. Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells.
Withey JM; Marley SB; Kaeda J; Harvey AJ; Crompton MR; Gordon MY
Br J Haematol; 2005 May; 129(3):377-80. PubMed ID: 15842662
[TBL] [Abstract][Full Text] [Related]
9. Comparison between molecularly defined and conventional therapeutics in a conditional BCR-ABL cell culture model.
Chaturvedi A; Battmer K; Schaefer D; Ganser A; Eder M; Scherr M
Oligonucleotides; 2007; 17(1):22-34. PubMed ID: 17461760
[TBL] [Abstract][Full Text] [Related]
10. RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.
Withey JM; Harvey AJ; Crompton MR
Leuk Res; 2006 May; 30(5):553-60. PubMed ID: 16260034
[TBL] [Abstract][Full Text] [Related]
11. Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation.
Rangatia J; Bonnet D
Leukemia; 2006 Jan; 20(1):68-76. PubMed ID: 16281073
[TBL] [Abstract][Full Text] [Related]
12. An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.
Liu JH; Wu SC; Chen WS; Yen CC; Yang MH; Tsai YC; Chen PM
Biochem Biophys Res Commun; 2004 Jun; 318(3):764-72. PubMed ID: 15144904
[TBL] [Abstract][Full Text] [Related]
13. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
Wang Z; Sampath J; Fukuda S; Pelus LM
Cancer Res; 2005 Sep; 65(18):8224-32. PubMed ID: 16166298
[TBL] [Abstract][Full Text] [Related]
14. FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells.
Le Y; Xu L; Lu J; Fang J; Nardi V; Chai L; Silberstein LE
Am J Hematol; 2009 May; 84(5):273-8. PubMed ID: 19358301
[TBL] [Abstract][Full Text] [Related]
15. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
16. RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells.
Futami M; Hatano T; Soda Y; Kobayashi S; Miyagishi M; Tojo A
Leukemia; 2008 Jun; 22(6):1131-8. PubMed ID: 18368071
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
[TBL] [Abstract][Full Text] [Related]
18. Silencing p21(Waf1/Cip1/Sdi1) expression increases gene transduction efficiency in primitive human hematopoietic cells.
Zhang J; Attar E; Cohen K; Crumpacker C; Scadden D
Gene Ther; 2005 Oct; 12(19):1444-52. PubMed ID: 15877047
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
20. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
Forster K; Obermeier A; Mitina O; Simon N; Warmuth M; Krause G; Hallek M
Ann Hematol; 2008 Mar; 87(3):183-93. PubMed ID: 17960378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
